GlassScriptPhysician profile
Ashley C Wagner
NPI 1205078706
$5,690.86
in general payments reported to CMS, 2019-2025
23 companies · $1,006 in 2025
The $1,006 reported for 2025 was more than what 80% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,320 · 2022: $1,184 · 2023: $1,092 · 2024: $1,089 · 2025: $1,006.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,918 · Education: $268.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,918.22 |
| Education | $268.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,669.95 | 2021-2025 | |
| Janssen Biotech, INC. | $774.59 | 2021-2025 | Tremfya, Simponi, Simponi Aria |
| Regeneron Healthcare Solutions, INC. | $535.82 | 2021-2025 | Dupixent, Libtayo |
| Sun Pharmaceutical Industries INC. | $436.35 | 2021-2025 | Ilumya |
| Novartis Pharmaceuticals Corporation | $436.16 | 2021-2025 | |
| Genzyme Corporation | $414.90 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $281.40 | 2022-2025 | Sotyktu |
| Amgen INC. | $201.33 | 2021-2025 | Otezla, Otezla |
| Pfizer INC. | $141.54 | 2021-2025 | |
| Leo Pharma INC. | $126.20 | 2021-2024 | Adbry |
| Galderma Laboratories, L.P. | $120.51 | 2021-2025 | Nemluvio |
| Incyte Corporation | $115.55 | 2021-2024 | Opzelura |
| Lilly USA, LLC | $94.39 | 2021-2022 | |
| Allergan, INC. | $71.05 | 2022 | |
| Biofrontera INC. | $52.98 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nabriva Therapeutics, Plc | $51.42 | 2021-2022 | |
| Almirall LLC | $41.65 | 2023-2025 | Seysara, Klisyri |
| Arcutis Biotherapeutics, INC. | $35.49 | 2023-2025 | Zoryve |
| Hill Dermaceuticals, INC. | $25.80 | 2023 | Tolak |
| Stemline Therapeutics INC. | $25.36 | 2021 | |
| Ucb, INC. | $16.75 | 2024 | Bimzelx |
| Organogenesis INC. | $16.45 | 2024 | |
| Organon LLC | $5.22 | 2025 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.